Status:

RECRUITING

Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis

Lead Sponsor:

Montreal Heart Institute

Conditions:

Infective Endocarditis

Native Valve Endocarditis

Eligibility:

All Genders

18+ years

Brief Summary

The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria...

Eligibility Criteria

Inclusion

  • 18 years of age or older, capable to provide informed consent;
  • Referred for a FDG-PET/CT study
  • Classified as having Possible IE prior to FDG-PET/CT imaging;
  • Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan.

Exclusion

  • Subjects with prosthetic cardiac valve and/or CIED;
  • Pregnant or breastfeeding female;
  • Body mass index \> 45 kg/m2.

Key Trial Info

Start Date :

August 31 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

97 Patients enrolled

Trial Details

Trial ID

NCT04792281

Start Date

August 31 2021

End Date

December 31 2025

Last Update

November 22 2024

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, Canada, H2X 3E4

2

Montreal Heart Institute

Montreal, Quebec, Canada, H3l 3c1

3

Jewish General Hospital

Montreal, Quebec, Canada, H3T 1E2

4

McGill University Health Center

Montreal, Quebec, Canada, H4A 3J1

Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis | DecenTrialz